{"id":"W4303470808","doi":"10.1159/000527403","title":"Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety","year":2022,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"EVRAZ (Canada)","funders":"European Commission; European Federation of Pharmaceutical Industries and Associations; University of Pittsburgh","keywords":"Regorafenib; Cabozantinib; Discontinuation; Medicine; Hepatocellular carcinoma; Sorafenib; Hazard ratio; Propensity score matching; Adverse effect; Internal medicine; Oncology; Surgery; Confidence interval; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01010008,0.001732958,0.002994132,0.0008611378,0.0002056944,0.001212832,0.001240665,0.001194742,0.009116656],"category_scores_gemma":[0.01808064,0.0005276185,0.007927529,0.0007074906,0.0006891937,0.001046238,0.001563702,0.001981184,0.000527457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000990438,"about_ca_system_score_gemma":0.0008242823,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001446307,"about_ca_topic_score_gemma":0.001133752,"domain_scores_codex":[0.98606,0.01071441,0.0007227493,0.001103571,0.000940073,0.0004591269],"domain_scores_gemma":[0.9928087,0.004377,0.001711882,0.00057575,0.0002442459,0.0002824426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.8052886,0.00171306,0.01994128,0.004135375,0.09074791,0.0001198754,0.0002358978,0.01196896,0.00210723,0.002309757,0.001433027,0.05999891],"study_design_scores_gemma":[0.3975382,0.2225403,0.1030889,0.001221272,0.1672144,0.0008338209,0.000451537,0.07326982,0.007035024,0.01538302,0.01106067,0.0003630552],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9648502,0.01272746,0.01023599,0.0005795989,0.0007177874,0.002154891,0.003644351,0.000159256,0.004930304],"genre_scores_gemma":[0.9921641,0.0008100961,0.00333204,0.000289244,0.000105737,0.001225763,0.001141463,0.000017984,0.0009135263],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01010008,"threshold_uncertainty_score":0.053415,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1111477898344688,"score_gpt":0.3278793606080632,"score_spread":0.2167315707735943,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}